TITLE: Long-Acting Injectable Antipsychotic Medications for Schizophrenia: Changing Our Paradigms
OVERALL DESCRIPTION: Approximately 1.1% of the population worldwide has schizophrenia, a prevalence that is relatively high due to the chronic nature and early onset of this disorder. Adherence to antipsychotic medication is crucial for minimizing the symptoms of schizophrenia and maximizing the patient’s function in society. If a patient does not adhere to a medication plan, the likelihood that the patient will relapse after being stabilized symptomatically is greatly heightened. While oral medications are a tremendous help in controlling what used to be a disease that warranted permanent institutionalization, patients often struggle with full adherence with these agents for a variety of reasons. Long-acting injectable antipsychotic drugs can be integral in assisting certain patients in managing their illness, even those with first-episode schizophrenia.
JOINTLY SPONSORED BY: University of Cincinnati College of Medicine and Haymarket Medical Education (HME)
IN COLLABORATION WITH: Schizophrenia and Related Disorders Alliance of America (SARDAA)
This educational grant is supported by Otsuka America Pharmaceutical, Inc. and Janssen Pharmaceuticals
- Charles L. Raison, MD, Professor, Department of Psychiatry, College of Medicine
- Barry and Janet Lang Professor, John and Doris Norton School of Family and Consumer Sciences, Tucson, AZ
Disclaimer: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SARDAA.